Savara Inc. (NASDAQ:SVRA) Director Acquires $98,379.00 in Stock

Savara Inc. (NASDAQ:SVRA) Director Richard J. Hawkins acquired 48,225 shares of the stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of $2.04 per share, with a total value of $98,379.00. Following the purchase, the director now owns 115,466 shares of the company’s stock, valued at approximately $235,550.64. This trade represents a 71.72% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Savara Stock Up 4.9%

NASDAQ SVRA traded up $0.10 on Monday, hitting $2.16. 855,181 shares of the stock were exchanged, compared to its average volume of 1,418,657. The company has a quick ratio of 14.91, a current ratio of 14.91 and a debt-to-equity ratio of 0.20. Savara Inc. has a fifty-two week low of $1.89 and a fifty-two week high of $5.11. The company has a market cap of $373.33 million, a PE ratio of -4.50 and a beta of 0.32. The company has a 50-day moving average price of $2.76 and a 200-day moving average price of $2.83.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). Sell-side analysts anticipate that Savara Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SVRA. HC Wainwright lowered shares of Savara from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $6.00 to $2.00 in a research note on Thursday, May 29th. Guggenheim reiterated a “buy” rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a report on Wednesday, May 28th. Finally, Wells Fargo & Company lowered their price target on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 28th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.17.

Institutional Trading of Savara

Several institutional investors have recently modified their holdings of SVRA. Bain Capital Life Sciences Investors LLC lifted its position in shares of Savara by 20.8% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after buying an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in shares of Savara by 32.4% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock valued at $31,751,000 after acquiring an additional 2,801,922 shares during the period. Vestal Point Capital LP increased its holdings in shares of Savara by 33.2% in the 4th quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock valued at $33,079,000 after acquiring an additional 2,685,000 shares during the period. Rosalind Advisors Inc. acquired a new position in shares of Savara in the 4th quarter valued at $8,151,000. Finally, Nantahala Capital Management LLC increased its holdings in shares of Savara by 45.2% in the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock valued at $23,103,000 after acquiring an additional 2,344,308 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.